Mater Researchers make early breakthrough with cancer vaccines

Tuesday 07 July 2020

*Update 22 July 2020*

Please note that that Associate Professor Radford’s work has not yet progressed to human clinical trials. We need your help to make this happen.

Your donation will make a direct impact to the lives of people living with cancer today.  Support clinical trials

Mater researchers, in partnership with The University of Queensland, have achieved publication in the highly-ranked journal ‘Clinical and Translational Immunology’. The article details their work to develop a new cancer vaccine, which has shown promising signs in preclinical laboratory studies.

Developed with support from Worldwide Cancer Research in the United Kingdom, and Mater Foundation, this vaccine could potentially be used to treat a variety of blood cancers and malignancies.

Lead Researcher Associate Professor Kristen Radford deems this study to be a major breakthrough for cancer vaccinations. 

“We are hoping this [vaccine] could be used to treat blood cancers, (myeloid leukaemia, non-Hodgkin’s lymphoma, multiple myeloma, paediatric leukaemias) plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma,” she said.

“The team have developed a new vaccine, comprised of human antibodies fused with tumour-specific protein, and are investigating its capacity to target human cells while activating the memory of the tumour cells.”

Associate Professor Radford explains that the vaccine offers several key advantages over existing cancer vaccines, that have already shown promise in early clinical trials.

“First, it can be produced as an ‘off the shelf’ clinical grade formulation, which circumvents the financial and logistical issues associated with patient-specific vaccines,” she said.

“Secondly, this prototype vaccine targets the key tumour cells required for the initiation of tumour-specific immune responses, thereby maximising potential effectiveness of treatment, while minimising potential side effects.

“We are very happy to see our research published in this prestigious journal, and we hope our continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future.”  

You can read the full academic article here at,